Study summary

A new pill plus immunotherapy modestly extended survival in later-line disease

STELLAR-303 trial (zanzalintinib plus atezolizumab) · 901 people, phase 3 · Published October 2025, The Lancet

10.9months median survival, vs 9.4 with regorafenib

What was tested

Zanzalintinib, a multi-target kinase inhibitor, plus atezolizumab against regorafenib for previously treated metastatic colorectal cancer that is not MSI-high.

What they found

What it means

One of the first immunotherapy combinations to extend survival in standard (MSS) colorectal cancer.

Lancet, via PubMed ↗ Trial record NCT05425940 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.